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ABSTRACT: The choanoflagellate Salpingoeca rosetta is a
microbial marine eukaryote that can switch between
unicellular and multicellular states. As one of the closest
living relatives of animals, this organism has become a
model for understanding how multicellularity evolved in
the animal lineage. Previously our laboratories isolated and
synthesized a bacterially produced sulfonolipid that
induces S. rosetta to form multicellular “rosettes.” In this
study, we report the identification of a bacterially produced
inhibitor of rosettes (IOR-1) as well as the total synthesis
of this molecule and all of its stereoisomers. Our results
confirm the previously noted specificity and potency of
rosette-modulating molecules, expand our understanding
of the complex chemical ecology between choanoflagel-
lates and rosette-inducing bacteria, and provide a synthetic
probe template for conducting further mechanistic studies
on the emergence of multicellularity.
Choanoflagellates are motile microbial eukaryotes thatreside in aquatic environments and feed on bacteria.
Much like the collar cells of sponges, these microscopic
organisms use a single apical flagellum to sweep surrounding
bacteria into their actin-rich collar, where the bacteria are
phagocytosed.1 Choanoflagellates, which are the closest living
relatives of animals, express diverse genes, such as C-type
lectins, cadherins, and tyrosine kinases, that are known to
regulate multicellular processes in animals.2−5 While predom-
inately unicellular, several species of choanoflagellate, including
Salpingoeca rosetta, alternate between unicellular and multi-
cellular states. In an embryogenesis-like process, the multi-
cellular form, known as a “rosette,” arises through multiple
rounds of cell division in which the sister cells do not
completely separate from each other (see the Supporting
Information for an image of a rosette).6,7 While full mechanistic
understanding of rosette development is yet to be achieved,
further study of the transition to multicellularity in this ancient
organism could provide meaningful insights into how multi-
cellularity evolved in the animal lineage.
We previously showed that the transition between the
unicellular form and the multicellular rosette is induced by a
sulfonolipid produced by Algoriphagus machipongonensis
(“Algoriphagus” for short), a marine bacterium originally
coisolated with S. rosetta that serves as prey for the
choanoflagellate.8,9 Subsequent synthesis of the inducing
molecule, termed rosette-inducing factor-1 (RIF-1), revealed
the absolute configuration of the molecule as well as the strict
stereochemical requirements for activity (Figure 1).10
However, while RIF-1 could induce a small percentage of
cells to form rosettes, the activity of RIF-1 alone did not
faithfully recapitulate the activity observed with live bacteria or
conditioned medium. Additionally, we noted apparent
fluctuations in the activity of isolated (natural) RIF-1, as well
as sphingolipid-enriched extracts, leading us to hypothesize that
Algoriphagus produces additional choanoflagellate-modulating
molecules that could serve as alternative inducers, synergists, or
possibly even inhibitors. In this report, we describe the isolation
and synthesis of a bacterially produced sulfonate-containing
lipid that inhibits sulfonolipid-induced rosette formation in S.
rosetta.
We performed a chloroform/methanol extraction on the cell
pellet of Algoriphagus and fractionated the extract by reversed-
phase (C-18) HPLC using a broad elution range in order to
expand our search beyond sulfonolipids.8 We then tested each
fraction in combination with inducers of rosette development
to determine whether any of the fractions contained molecules
with inhibitory activity. As inducers we used either a
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Figure 1. Previously isolated rosette-inducing molecules RIF-1 and
RIF-2 and inhibitor of rosettes (IOR-1).
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sulfonolipid-enriched fraction (RIF-mix) that elicits high levels
of rosette formation (with up to 30% of cells in rosettes) or a
purified sulfonolipid, RIF-2, a close structural analogue of RIF-1
whose complete stereostructure remains to be fully elucidated
(Woznica and Cantley et al., submitted; Figure 1). We
identified two adjacent fractions that reduced rosette formation
when treated in combination with either RIF-mix or RIF-2.
High-resolution mass spectrometry revealed that both
fractions predominately contained a molecule with a mass of
[M − H] 351.2216 Da, matching a predicted formula of
C17H35O5S. One- and two-dimensional NMR experiments
(Figures S1−S6) permitted us to propose a planar structure for
this molecule, which we have named inhibitor of rosettes (IOR-
1) (Figure 1). IOR-1 is optically active ([α]D
22 = +24, c 0.125,
MeOH), and its absolute configuration was ultimately
determined through synthesis as described below. Dose−
response curves using purified IOR-1 showed an optimal
inhibitory concentration of 2.5 nM (Figure 2), which
corresponds with our observation of IOR-1’s single-digit-
nanomolar concentration in Algoriphagus-conditioned medium
(Supporting Information, Methods).
We were intrigued by the structure of IOR-1 for several
reasons. It resembles the capnine base found in bacterially
produced sulfonolipids, especially in that it contains the
sulfonic acid headgroup present in the previously identified
RIF-1 and RIF-2. As capnine bases, like the analogous
sphingoid bases, are biosynthetically derived from amino
acids, the 2-position typically has an −NH2 substituent, so
the −OH group at this position on IOR-1 is a notable
modification. In general little is known about capnines, and
while they have been postulated to facilitate bacterial gliding,
their functions are not well understood and their distribution is
quite limited.11,12 The more common class of sphingosine bases
(or lysosphingolipids) act through G protein-coupled receptors
to modulate diverse biological processes including triggering
apoptosis and mediating inflammation.13−15 The structural
similarity between IOR-1 and these signaling molecules
suggests that they may also share functional similarities.
We synthesized IOR-1 both to establish its absolute
stereostructure and to determine whether it shared the same
strict stereochemical requirements seen in RIF-1. Additionally,
the relatively simpler synthesis of IOR-1 compared with that of
RIF-1 makes IOR-based probes potentially valuable tools for
identifying the host targets of rosette-modulating molecules.
As we needed to access all four possible configurations of the
hydroxyl groups at C2 and C3, we reasoned that we could
reduce an alkyl chain ending in a propargylic alcohol to either
the corresponding cis- or trans-alkene and then perform
Sharpless asymmetric dihydroxylations on both alkenes using
either the α or β mix to yield all four stereoisomers. In a final
step, the sulfonic acid moiety could be added to each purified
stereoisomer through nucleophilic substitution.
To reach 15-methylhexadec-2-yn-1-ol (3), we started with
commercially available 10-undecyn-1-ol (1′). We elongated the
acyl chain and added the isopropyl tail through a Grignard
reaction with isopentyl-MgBr in the presence of Li2CuCl4 to
yield 2 in a manner similar to that described previously.16
Propargylic alcohol 3 was obtained through acetylide formation
and subsequent nucleophilic addition to paraformaldehyde.17
At this stage our synthetic strategy diverged to obtain both the
cis- and trans-alkene. We used Lindlar’s catalyst to reduce
alkyne 3 to the cis-alkene Z-4 in the presence of H2 and Red-Al
to obtain the trans-alkene E-4. These reductions were achieved
in acceptable yields of 74% and 70% respectively. From this
branch point we could access each diol configuration pattern
through asymmetric bishydroxylation using the Sharpless
reagents (AD mix-α and AD mix-β) in the presence of
Figure 2. Cotreatment of IOR-1 (2.5 nM) with RIF-2 and RIF-mix.
Graphs were generated using GraphPad Prism 6 statistical software.
The rosette induction data were analyzed using a one-site (specific
binding) model.
Scheme 1. Synthesis of IOR-1 Stereoisomers A−Da
aConditions: (a) TsCl, pyridine, CH2Cl2, 4 °C, 10 h. (b) Isopentyl-MgBr, THF, Li2CuCl4 (cat.), 0 °C to RT, overnight, 42% over two steps. (c)
THF, n-BuLi, PFA, 0 °C to RT, 2.5 h, 66%. (d) Lindlar’s catalyst, MeOH, H2, RT, overnight, 74%. (e) Red-Al, ether, 0 °C to RT, overnight, 70%. (f)
AD mix-β, H2O, t-BuOH, methanesulfonamide, 0 °C, 6−24 h, 77−87%. (g) AD mix-α, H2O, t-BuOH, methanesulfonamide, 0 °C, 6−24 h, 73−82%.
(h) TsCl, pyridine, DCM, 4 °C, 10 h. Note: at this step, tosylated compounds were purified by chiral HPLC to give the pure enantiomers. (i)
Na2SO3, H2O, EtOH, 62 °C, overnight, 14−20%.
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methanesulfonamide, which afforded yields in the 70−80%
range.18 This stage proved suitable to purify the diols via chiral
chromatography, yielding enantiopure 6A, 6B, 6C, and 6D
(Scheme 1; also see Figures S7−S23).
Although we previously introduced the sulfonic acid moiety
of RIF-1 through a Mitsonobu reaction using thioacetic acid
followed by oxidation, with tosylates 6A-D in hand a simple
nucleophilic displacement strategy at this position was more
efficient. While substitution with thioacetic acid and subsequent
oxidation yielded IOR-1, side-product formation frustrated the
final purification. Addition of sodium sulfite in a heated biphasic
solution of water and ethanol yielded fewer side products and,
while giving a low yield of the final product (14−20%), allowed
a much simpler purification process and higher overall
conversion.19
The 1H NMR spectra of compounds IOR-1A and IOR-1B
were identical to that of isolated IOR-1 (Figures S24−S26),
whereas compounds IOR-1C and IOR-1D exhibited different
chemical shifts of protons at positions C1, C2, and C3.
Determination of the optical rotations for these molecules
revealed matching signs and values for IOR-1A and IOR-1
(Supporting Information, Methods), suggesting that IOR-1A is
likely a match to the isolated molecule.
To verify the activity and specificity of IOR-1, we tested each
of the synthetic stereoisomers in our rosette inhibition assay.
Full dose−response curves revealed almost identical activity for
IOR-1A compared to the isolated inhibitor, whereas IOR-1B
displayed no activity (Figure 3); unsurprisingly, IOR-1C and
IOR-1D were also inactive (Figure S27). Given both the
spectroscopic and biological data, we were able to determine
the absolute configuration of IOR-1 as 2S,3R. Significantly, only
one stereoisomer of the inhibitor is active, reprising the theme
that these molecules interact in a highly specific manner with
their target. We further validated this specificity by testing a
handful of commercially available IOR-1 analogues, and none
were active at concentrations ranging from 0.1 ng/mL to 1 μg/
mL (Figure S28).
Furthermore, this specificity suggests that IOR-1 (IOR-1A) is
an appropriate starting point for the development of a
bioaffinity probe that could be used to investigate the
choanoflagellate target and mechanism of rosette-modulating
molecules. Its straightforward synthesis and scalability allows
for quick access to modified versions of IOR-1, and its potency
(2.5 nM) would minimize the likelihood of nonspecific
interactions even if the probes were of somewhat lower
potency. Our synthetic route also supplies us with inactive
stereoisomers of IOR-1, which can serve as useful negative
controls for target identification.
The assignment of the hydroxyls of IOR-1 in the syn
configuration was unexpected; we had predicted that the
hydroxyls would have the same relative configuration as the 2-
amine and 3-hydroxyl groups observed in RIF-1, which is by far
the most common stereochemistry for sulfonolipids and
sphingolipids.13 While not unprecendented, it is quite rare for
capnine bases to exhibit the syn configuration, and biosynthesis
of the syn-diol has not been reported.20,21 Exploration of the
fully annotated genome of Algoriphagus confirmed the presence
of a number of transaminases, which could invert the
configuration of the hydroxyl group at C2 during conversion
from an amino group (Figures S29 and S30).22 As the
biosynthesis of IOR-1 clearly has components that are distinct
from the known sulfonolipids (cf. RIF-1), this molecule is
unlikely to be either a degradation product or a precursor to the
more standard sphingolipids and sulfonolipids. Further
investigation into the biosynthesis and regulation of IOR-1
are ongoing and will be of great interest in understanding the
ecological context in which these molecules are produced.
From an ecological perspective, the isolation and character-
ization of IOR-1 raises a number of interesting questions about
the choanoflagellate−bacterium predator−prey relationship.
The isolation of both an inducer and an inhibitor from the
same bacterium highlights the complexity of the relationship
between Algoriphagus and S. rosetta. Our current hypothesis is
that rosette formation improves bacterial prey capture by
choanoflagellates, and if this is true, production of factors that
attenuate rosette-colony formation would confer an apparent
benefit to the producing bacteria.23 Understanding how IOR-1
and RIFs are produced and regulated should begin to reveal
how Algoriphagus could use both sets of molecules to
manipulate its predators. More generally, examining the
complex phenotypic effects triggered by these bacterially
produced small molecules will increase our understanding of
the role of bacteria in the evolution of multicellular organisms.
In summary, we have isolated, characterized, and synthesized
an atypical sulfonolipid that potently inhibits the conversion
from a unicellular to a multicellular morphology in choano-
flagellates. Through synthesis we were able to confirm that this
lipid has the rare syn-diol configuration and that the 2S,3R
stereochemistry is necessary for activity. The discovery of this
molecule reveals that the chemical interaction between
choanoflagellates and rosette-inducing bacteria is more complex
than previously imagined and argues that further investigation
is warranted. Finally, IOR-1 provides a starting point for
pathway identification in this important model system.
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